[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"quantitative-sensory-testing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:quantitative-sensory-testing":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642999","investigation-of-pain-modulation-phenotypes-in-female-patients-with-fibromyalgia-100642999",false,"NCT07640607","Investigation of Pain Modulation Phenotypes in Female Patients With Fibromyalgia","Inclusion Criteria:\n\n1. Having received a diagnosis of fibromyalgia according to the 2016 ACR diagnostic criteria\n2. Female patients aged 18-65\n3. Being literate\n4. Having signed the informed consent form upon agreeing to participate in the study\n\nExclusion Criteria:\n\n1. Being under 18 or over 65 years of age\n2. Having any condition that may lower the pain threshold or cause chronic pain (Rheumatoid Arthritis, Ankylosing Spondylitis, systemic inflammatory diseases, malignancies, etc.)\n3. Any neurological condition (stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, central nervous system malignancies…)\n4. Peripheral artery disease\n5. Severe cardiopulmonary insufficiency (stage 3-4)\n6. Uncontrolled systemic diseases such as hypertension and diabetes\n7. Presence of an active infection\n8. Pregnancy\n9. Presence of cognitive impairment, hearing loss, or communication difficulties that would prevent understanding of questionnaires and protocols","FEMALE","18 Years","65 Years",{"count":19,"type":20},82,"ESTIMATED","OBSERVATIONAL","Fibromyalgia is characterized by altered pain processing, including impaired descending pain inhibition and central sensitization. While both mechanisms have been independently associated with disease severity, their interrelationship remains unclear. This cross-sectional study aims to investigate whether central sensitization symptoms mediate the relationship between conditioned pain modulation and fibromyalgia impact.",[24,25,26,27,28],"Fibromyalgia (FM)","Quantitative Sensory Testing","Central Sensitization","PRESSURE PAIN THRESHOLD","Pain Perception",[30,31,32],"Fibromyalgia","Pain sensitization","Conditioned pain modulation","NOT_YET_RECRUITING","2026-06-05",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":20},"2026-06-01",{"date":41,"type":20},"2026-09-01",{"name":43,"class":44},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":16,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":74,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100600783","hyperthermia-in-patients-with-chronic-primary-pain---effects-on-thermoregulation-somatosensory-system-and-movement-evoked-pain-100600783","NCT07101978","Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain","Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)","HYPPRI-1","Inclusion Criteria:\n\npatients:\n\n* Confirmed diagnosis of widespread pain (ICD-11 MG30.01)\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9,\n* Pain \\>= 3 month and VAS \\>= 4,0\n* Body - infrared-A-Bulb Distance \\\u003C 38cm (overweight participants)\n* Signed declaration of consent\n\nhealthy:\n\n* No chronic illnesses\n* No acute infections\n* No regular medication: To avoid interactions\n* BMI ≤ 40kg\u002Fcm2\n* Mental health: No psychiatric diagnoses or psychotropic medication in your medical history\n\nExclusion Criteria:\n\n* Participation in other clinical studies\n* Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)\n* Acute and \u002F or feverish microbial infections\n* Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases\n* participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha\u002Fbeta-A(nta)gonists due to a disease from the group described above\n* participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders\n* pregnancy or breastfeeding (for women)\n* Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group",true,"ALL","70 Years",{"count":57,"type":20},60,"INTERVENTIONAL",[60],"NA","This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.",[63,64,65,66,67,68,69,30,70,71,72,25,73],"Hyperthermia","Chronic Primary Pain","Widespread Pain","Muscular Disease","Rheumatic Diseases","Musculoskeletal Diseases","Neuromuscular Disease","Circadian Rhythm","Body Temperature Changes","Somatosensory Function","Healthy",[75,76,77,78,79,80],"hyperthermia","widespread pain","chronic primary pain","circadian body temperature","quantitative sensory testing","healthy","2026-05-29",{"date":83,"type":37},"2026-06-02",{"date":85,"type":20},"2026-08-01",{"date":87,"type":20},"2028-12-31",{"name":89,"class":44},"Bern University of Applied Sciences",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":54,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":58,"phases":102,"briefSummary":103,"conditions":104,"keywords":112,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":90},"100571845","integrative-medicine-in-pain-management-in-sickle-cell-disease-20-100571845","NCT06725550","Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0","Integrative Medicine in Pain Management in Sickle Cell Disease: Assessing the Clinical Efficacy and Neurobiological Impact With Acupuncture, 2.0","Inclusion Criteria:\n\n* Any gender\n* 14-17 (Adolescents) and 18-80 (Adults) years old\n* Right-handed\n* Either outpatient or inpatient or status changing between each other\n* Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months.\n* Analgesic therapy prescribed by primary hematologists (or physicians for emergency or primary care) including pain-relieving medications (e.g. Morphine, coderin, Fentanyl, Oxycodone), Hydroxyurea (e.g. Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta), and\u002For other palliative treatment allowed, not required.\n* Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits.\n* Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupuncture treatments up to two times weekly for 5 weeks as scheduled.\n* We will recruit without regard to ethnicity, however, due to the genetic nature of SCD, subjects will primarily be African-American or of African descent, although there are individuals with SCD who come from Hispanic, southern European, Middle Eastern, or Asian Indian backgrounds. The ethnic distribution in our prior studies is 95% Black\u002FAfrican American with 5% Hispanic or Latino (of any race). As these are minority groups many individuals may be from lower income situations.\n* Fluent in English and capable of giving written informed consent.\n\nExclusion Criteria:\n\n* Subjects with Covid-19 suspicion or confirmation\n* Recent\u002Fongoing alternative pain management with acupuncture or acupuncture-related techniques within the last 6-months.\n* Presence of a known coagulation abnormality: Thrombocytopenia (mild thrombocytopenia with a platelets range of 51,000-100,000\u002Ful will be further evaluated for inclusion consideration), or bleeding diathesis that may preclude the safe use of acupuncture.\n* Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain or any other chronic pain condition with pain greater than sickle pain.\n* Diseases\u002Fconditions history includes but not limited to:\n\n  * head injury with substantial loss of consciousness\n  * peripheral neuropathy of known cause that interferes with activities of daily living\n  * known non-SCD related Severe psychiatric illnesses (e.g. current schizophrenia, major depression with suicidal ideation).\n  * significant visual, motor, or auditory impairment that would interfere with ability to perform study visits-related activities\n* Medication:\n\nRecent (30 days) initiation or dose adjustment of stimulant medications, such as those used to treat ADD\u002FADHD (e.g., amphetamine\u002Fdextroamphetamine \\[Adderall®\\], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil).\n\n* Contraindications to MRI scans includes but are not limited to: surgical clips, surgical staples, metal implants, cardiac rhythmic disorders, seizure disorders, and certain metallic dental material will not be scheduled for MRI visits.\n* History vascular surgery in lower limbs or current lower limb vascular dysfunction will not receive conditioned pressure pain stimuli in the lower limb.\n* Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's sickle disease; current involvement in out-of-court settlements for claims pertinent to the subject's sickle disease; or currently receiving monetary compensation as a result of any of the above.\n* Participation of other studies: Concurrent participation in other therapeutic trials with overlapping research purposes.\n* Pregnant or nursing.","14 Years","80 Years",{"count":101,"type":20},120,[60],"The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.",[105,106,107,25,108,109,110,111],"Sickle Cell Disease","Pain","Acupuncture","Magnetic Resonance Imaging","Circulating Biomarkers","Electroencephalography","Functional Near-infrared Spectroscopy",[113,106,107,25,108,109,110,111],"Sickle cell disease","RECRUITING","2025-10-15",{"date":117,"type":37},"2025-10-20",{"date":119,"type":37},"2025-08-25",{"date":121,"type":20},"2030-08-30",{"name":123,"class":44},"Indiana University"]